Ocugen, INC. (OCGN) — SEC Filings

Overview

Ocugen, INC. (OCGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 24, 2026: Ocugen, Inc. filed an 8-K on March 24, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are publicly disclosing information that was not previously public. This filing includes three exhibits (99.1, 99.2, and 99.3) which likely contain the new material information, along with numerou

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bullish, 4 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Ocugen, INC. is neutral.

Filing Type Overview

Ocugen, INC. (OCGN) has filed 33 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 1 8-K/A, 2 SC 13G/A, 3 SC 13G, 1 DEFA14A, 1 10-K/A with the SEC between Apr 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Ocugen Files 8-K for Regulation FD Disclosure on March 24, 2026 — 8-K · Mar 24, 2026
  Ocugen, Inc. filed an 8-K on March 24, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are publicly disclosing information that was not previou
• Ocugen Reports Director/Officer Changes and Compensation — 8-K · Dec 18, 2025 Risk: medium
  Ocugen, Inc. filed an 8-K on December 18, 2025, reporting events as of December 12, 2025. The filing indicates changes related to the departure of directors or
• Ocugen's Losses Widen to $50.1M Amid Soaring R&D Costs — 10-Q · Nov 5, 2025 Risk: high
  Ocugen, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $50.1 million, up from $40.2 million in the same
• Ocugen, Inc. Files 8-K on Financials — 8-K · Nov 5, 2025 Risk: low
  Ocugen, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
• Ocugen Terminates Material Definitive Agreement — 8-K · Sep 18, 2025 Risk: medium
  Ocugen, Inc. announced on September 16, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report o
• Ocugen Enters Material Definitive Agreement — 8-K · Sep 16, 2025 Risk: medium
  Ocugen, Inc. entered into a Material Definitive Agreement on September 11, 2025. The filing does not disclose the specific nature or terms of this agreement, on
• Ocugen Enters Material Definitive Agreement — 8-K · Sep 5, 2025 Risk: medium
  Ocugen, Inc. announced on August 29, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement,
• Ocugen, Inc. Enters Material Definitive Agreement — 8-K · Aug 11, 2025 Risk: medium
  Ocugen, Inc. announced on August 8, 2025, that it entered into a material definitive agreement. The company, formerly known as Histogenics Corp, is incorporated
• Ocugen's Q2 Net Loss Widens to $19.5M Amid R&D Push — 10-Q · Aug 4, 2025 Risk: high
  Ocugen, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three
• Ocugen Files 8-K on Financials — 8-K · Aug 1, 2025 Risk: low
  Ocugen, Inc. filed an 8-K on August 1, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
• Ocugen Closes $100M Public Offering — 8-K · Jul 30, 2025 Risk: medium
  On July 29, 2025, Ocugen, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised approximately $10
• Ocugen to Acquire Ocuphire Pharma for $100M — 8-K · Jul 29, 2025 Risk: medium
  Ocugen, Inc. announced on July 29, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of Ocuphire Pharma, Inc. fo
• Ocugen Faces Delisting Notice — 8-K · Jul 1, 2025 Risk: high
  Ocugen, Inc. filed an 8-K on July 1, 2025, to report a notice of delisting or failure to meet continued listing standards. The company is based in Malvern, Penn
• Ocugen, Inc. Files 8-K: Material Agreement & Financials — 8-K · Jun 23, 2025 Risk: medium
  On June 22, 2025, Ocugen, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial statements and
• Ocugen, Inc. Files 8-K Report — 8-K · Jun 17, 2025 Risk: low
  On June 16, 2025, Ocugen, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is involved in biolog
• Ocugen Files 8-K: Shareholder Vote, Other Events, Financials — 8-K · Jun 5, 2025 Risk: low
  On June 5, 2025, Ocugen, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders, other events, and financial statements and ex
• Ocugen Files Q1 2025 10-Q Report — 10-Q · May 9, 2025 Risk: medium
  Ocugen, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Key fi
• Ocugen Files 8-K: Regulation FD & Financials — 8-K · May 1, 2025 Risk: low
  Ocugen, Inc. filed an 8-K on May 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's status an
• Ocugen Files Definitive Proxy Statement for 2025 Shareholder Meeting — DEF 14A · Apr 25, 2025 Risk: low
  Ocugen, Inc. filed its definitive proxy statement (DEF 14A) on April 25, 2025, for its annual meeting on June 5, 2025. The filing details matters to be voted on
• Ocugen Reports Director/Officer Changes — 8-K · Apr 25, 2025 Risk: medium
  Ocugen, Inc. filed an 8-K on April 25, 2025, reporting events as of April 21, 2025. The filing pertains to the departure of directors or certain officers, elect
• Ocugen Files 8-K: Routine Update — 8-K · Apr 4, 2025 Risk: low
  Ocugen, Inc. filed an 8-K on April 4, 2025, reporting other events and financial statements. The filing does not detail specific new events or financial figures
• 10-K Filing — 10-K · Mar 5, 2025
• Ocugen, Inc. Files 8-K Reporting Other Events — 8-K · Mar 3, 2025 Risk: low
  Ocugen, Inc. filed an 8-K on March 3, 2025, reporting other events and financial statements. The filing does not contain specific details about new material eve
• Ocugen Files 8-K: Other Events & Financials — 8-K · Feb 12, 2025 Risk: low
  On February 12, 2025, Ocugen, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is involved in bi
• Ocugen Files 8-K/A Amendment — 8-K/A · Feb 7, 2025 Risk: medium
  Ocugen, Inc. filed an 8-K/A amendment on February 7, 2025, related to events occurring on November 6, 2024. The filing pertains to the entry into a material def
• Ocugen Files 8-K: Other Events & Financials — 8-K · Jan 29, 2025 Risk: low
  Ocugen, Inc. filed an 8-K on January 29, 2025, reporting other events and financial statements. The company, previously known as Histogenics Corp, is incorporat
• Ocugen Faces Delisting Concerns — 8-K · Jan 3, 2025 Risk: high
  Ocugen, Inc. filed an 8-K on January 3, 2025, reporting a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard as of December 31, 2024
• Ocugen Files 8-K for Other Events and Exhibits — 8-K · Dec 3, 2024 Risk: low
  Ocugen, Inc. filed an 8-K on December 3, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of
• Ocugen Board Shakeup & Officer Compensation Disclosed — 8-K · Nov 15, 2024 Risk: medium
  Ocugen, Inc. announced on November 14, 2024, a change in its board of directors. Dr. Anya Schiach, who served as a director, has resigned. The company also disc
• Ocugen Q3 Revenue Surges to $1.01M, R&D Costs Decline — 10-Q · Nov 14, 2024 Risk: medium
  Ocugen, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported revenue of $1.01 million for the third quarter of 2024, a significant
• Ocugen Files 8-K: Regulation FD & Exhibits — 8-K · Nov 12, 2024 Risk: low
  Ocugen, Inc. filed an 8-K on November 12, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain speci
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Ocugen Files 8-K: Material Agreement, Financial Obligation, Equity Sale — 8-K · Nov 8, 2024 Risk: medium
  Ocugen, Inc. announced on November 6, 2024, that it entered into a material definitive agreement. The company also disclosed the creation of a direct financial
• Ocugen Files 8-K on Operations and Financials — 8-K · Nov 8, 2024 Risk: medium
  Ocugen, Inc. filed an 8-K on November 8, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G Filing — SC 13G · Oct 22, 2024
• SC 13G Filing — SC 13G · Oct 16, 2024
• Ocugen, Inc. Files 8-K Report — 8-K · Aug 13, 2024 Risk: medium
  On August 13, 2024, Ocugen, Inc. filed an 8-K report, indicating a significant corporate event. The filing does not detail specific financial transactions or st
• Ocugen Files 10-Q for Q2 2024 — 10-Q · Aug 8, 2024 Risk: medium
  Ocugen, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key
• Ocugen Files 8-K: Routine Update — 8-K · Aug 5, 2024 Risk: low
  Ocugen, Inc. filed an 8-K on August 5, 2024, reporting other events and financial statements. The filing does not contain specific details about new material ev
• Ocugen, Inc. Files 8-K with Material Agreements — 8-K · Aug 1, 2024 Risk: medium
  On July 31, 2024, Ocugen, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported other
• Ocugen Appoints New Auditor, Dismisses PricewaterhouseCoopers — 8-K · Jul 8, 2024 Risk: medium
  Ocugen, Inc. announced on July 2, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP as its independent registere
• Ocugen Files 8-K on Security Holder Vote — 8-K · Jun 28, 2024 Risk: low
  Ocugen, Inc. filed an 8-K on June 28, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about the spec
• Ocugen Files Proxy Statement Supplement — DEFA14A · Jun 18, 2024 Risk: low
  Ocugen, Inc. filed a Definitive Proxy Statement (DEFA14A) on June 18, 2024, supplementing its Notice of Annual Meeting of Stockholders. The filing, originating
• Ocugen Acquires Innovimmune Biotherapeutics for $15M — 8-K · Jun 6, 2024 Risk: medium
  Ocugen, Inc. announced on May 31, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of Innovimmune Biothe
• Ocugen Files Definitive Proxy Statement for 2024 Shareholder Meeting — DEF 14A · May 28, 2024 Risk: medium
  Ocugen, Inc. filed its definitive proxy statement for the 2024 Annual Meeting of Stockholders, scheduled for June 28, 2024. The filing outlines proposals for th
• Ocugen, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: medium
  Ocugen, Inc. (OCGN) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Ocugen, Inc. filed a 10-Q report for the period ending March 31, 2024. The fil
• Ocugen Files 8-K: Rights, Bylaws, and Financials Updated — 8-K · May 10, 2024 Risk: medium
  Ocugen, Inc. filed an 8-K on May 10, 2024, reporting material modifications to the rights of security holders and amendments to its articles of incorporation or
• Ocugen, Inc. Files 10-K/A Amendment — 10-K/A · Apr 29, 2024 Risk: low
  Ocugen, Inc. (OCGN) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Ocugen, Inc. filed an amendment (10-K/A) to its annual report for the

Risk Profile

Risk Assessment: Of OCGN's 43 recent filings, 4 were flagged as high-risk, 23 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Ocugen, INC.'s most recent 10-Q filing (Nov 5, 2025):

• Revenue: $4.6M
• Net Income: -$50.1M
• EPS: -$0.07
• Debt-to-Equity: 15.30
• Cash Position: $32.6M
• Operating Margin: -997.1%
• Total Assets: $57.6M
• Total Debt: $28.4M

Key Executives

• Anya Schiach

Industry Context

Ocugen operates in the highly competitive and capital-intensive biotechnology sector, focusing on gene therapies for rare eye diseases. The industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles. Success hinges on clinical trial outcomes and successful navigation of FDA approvals.

Top Tags

filing (7) · 8-K (6) · corporate-governance (5) · sec-filing (5) · financials (5) · material-agreement (4) · biotech (4) · corporate-update (4) · disclosure (3) · Biotechnology (3)

Key Numbers

• Accession Number: 123610 — Unique identifier for the filing
• Filing Date: 20251218 — Date the report was submitted to the SEC
• Report Date: 20251212 — Date of the earliest event reported
• Net Loss: $50.1M — Increased from $40.2M in 2024, a 24.6% rise, indicating worsening financial performance.
• Accumulated Deficit: $390.4M — As of September 30, 2025, highlighting significant historical losses and financial strain.
• Cash Balance: $32.6M — As of September 30, 2025, down from $58.5M at December 31, 2024, insufficient for 12 months of operations.
• Research and Development Expenses: $29.1M — Increased from $23.8M in 2024, a 22.3% rise, reflecting continued investment in pipeline but also higher cash burn.
• Collaborative Arrangement Revenue: $4.6M — Increased from $3.3M in 2024, showing some revenue growth but still minimal compared to expenses.
• Outstanding Common Shares: 312,320,112 — As of October 31, 2025, indicating potential dilution from capital raises.
• Net Loss Per Share: $0.07 — For the three months ended September 30, 2025, compared to $0.05 in 2024, reflecting increased losses per share.
• Revenue: $0 — for Q2 2025 and Q2 2024, indicating no commercial products
• R&D Expenses: $14.2M — for Q2 2025, increased from $12.8M in Q2 2024
• Increase in Net Loss: 10.8% — from Q2 2024 to Q2 2025
• Gross Proceeds: $100.0M — Raised from public offering before expenses.
• Shares Sold: 10.0M — Number of common stock shares sold in the offering.

Frequently Asked Questions